< Back

February, 2018

Capabilities and Engagement Determine Opportunities with Key Payers

Leading Health Plans and PBMs | Research Released February 2018

Capabilities and Engagement Determine Opportunities with Key Payers

Across payers, level of sophistication and control, expertise in value and quality, and approach to innovation typically correlate with engagement opportunities for biopharmaceutical companies.

Aetna, Humana, and CVS Caremark remain high-opportunity payers for biopharmaceutical companies, given their ability to drive access, interest in value-based initiatives, infrastructure for advanced analytics, and consistent interest in biopharmaceutical company relationships and support.

EnvisionRx and Centene offer limited opportunities as they typically refrain from engaging with biopharmaceutical companies and lack sufficient sophistication and/or control to develop advanced relationships.

Aetna, CVS Caremark, and Humana Lead Payers in Capabilities and Engagement

leading health plans and PBMs

download research slide

 

These and other findings can be found in Health Strategies Group’s recently released research Executive Summary: Comparison of Key Account and Account Segments.

Key Topics Covered in this research:

  • Level of sophistication and control
  • Focus and performance on value and quality
  • Approach to innovation
  • Biopharma engagement

research agenda

 

Visit the Leading Health Plans and PBMs webpage to learn more about this research.

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.